Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL)
Phase I/II Study With Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-hodgkin's Lymphoma (NHL) Not Eligible for High Dose Chemotherapy and Autologous/Allogeneic Stem Cell Transplantation
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Forventet)
Tilmelding
Fase
Fase
- Fase 2
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
-
Berlin, Tyskland, 10117
- Dept. of Hematology and Oncology, Charité, Campus Charité Mitte
-
Berlin, Tyskland, 12203
- Dept. of Hematology and Oncology, Charité, Campus Benjamin Franklin
-
Berlin, Tyskland, 13353
- Dept. of Hematology and Oncology, Charité, Campus Virchow Klinikum Charité
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Age 18 years or older
- Mantle Cell Lymphoma according to REAL/WHO classification
- First or second relapse or alternatively progression during therapy. Previous use of Bendamustine is permitted, if the patient has reached at least partial remission and progression occured more than 6 months after therapy. Previous high dose chemotherapy with auto-SCT is permitted, if the patient has reached at least partial remission and progression occured more than 12 months after therapy.
- Patients must not be eligible for high dose chemotherapy with auto-SCT or allo-SCT.
- Adequate bone marrow function (hemoglobin > 9g/dl, platelet count >100/nL, absolute neutrophil count >1,5 /nL)
- WHO/ECOG Performance Status 0-2
- Measurable disease (two perpendicular diameters by either physical or radiological examination)
- Life expectancy ≥ 3 weeks
- Written informed consent
Exclusion Criteria:
- Prior treatment with any m-TOR Inhibitor
- Unstable or severe uncontrolled medical condition (e.g. severe congestive heart failure, myocardial infarction within the past 6 months, severe, uncontrolled arterial hypertension, renal insufficiency requiring hemodialysis, severe pulmonary disease, severe diabetes)
- Abnormal liver function: transaminases or total bilirubin > 2 x upper limit of normal (ULN)
- Abnormal renal function: serum creatinine > 2 x upper limit of normal
- Previous malignancy other than non-melanoma skin cancer or carcinoma in situ of the cervix.
- Concurrent treatment with strong inhibitors of CYP3A4 and/or inducers of CYP3A4
- Pregnant or breastfeeding women (negative pregnancy test not older than 7 days is required for women of fertile age). Men and women of child-bearing potential must agree to use adequate contraception (i.e. failure rate < 1% p.a. )
- Major surgery within 4 weeks before study entry; minor procedures (e.g. Implantation i.v. port catheter, Lymphnode biopsy) within 1 week before study entry
- Previous therapy with any investigational agents within 28 days before study entry
- Concomitant immunotherapy (e.g. Rituximab) or Chemotherapy other than Bendamustine. Use of systemic steroids should be documented and the Principal Investigator be informed.
- Central nervous system (CNS) lymphomatous involvement
- HIV positivity
- Current or chronic hepatitis B or hepatitis C infection
- Severe psychiatric illness or Individuals that are placed in an institution due to a magisterial or judiciary command.
- Inability to comply with study requirements
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Phase I: Dose-finding
Tidsramme: 6 months
|
Is the combination of temsirolimus alongside with bendamustine at the suggested dose feasible or are dose reductions necessary.
Number of dose reductions or delays of therapy due to hematologic toxicities (CTCAE) or other adverse events according to protocoll.
|
6 months
|
|
Phase II: Response Rate (Overall response rate, complete and partial response)
Tidsramme: 6 months
|
What is the response rate of a therapy with temsirolimus and bendamustine.
|
6 months
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Progression free survival
Tidsramme: 2 years
|
This is defined as the period of time between the admission into the clinical trial and the progression of the lymphoma or death of any kind.
|
2 years
|
|
Safety and Tolerability of Temsirolimus and Bendamustine Combination Therapy
Tidsramme: 2 years
|
Detection of overall toxicity, serious adverse events (SAE), suspected unexpected serious adverse reactions (SUSAR) during treatment with temsirolimus and bendamustine.
|
2 years
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Efterforskere
Efterforskere
- Ledende efterforsker: Christian Scholz, PD Dr., Charite University, Berlin, Germany
Datoer for undersøgelser
Studer store datoer
Studiestart
Studiestart
Primær færdiggørelse (Forventet)
Primær færdiggørelse
Studieafslutning (Forventet)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Sygdomme i immunsystemet
- Neoplasmer efter histologisk type
- Neoplasmer
- Lymfoproliferative lidelser
- Lymfesygdomme
- Immunproliferative lidelser
- Lymfom
- Lymfom, Non-Hodgkin
- Lymfom, kappecelle
- Lægemidlers fysiologiske virkninger
- Molekylære mekanismer for farmakologisk virkning
- Anti-infektionsmidler
- Antineoplastiske midler
- Immunsuppressive midler
- Immunologiske faktorer
- Antineoplastiske midler, Alkylering
- Alkyleringsmidler
- Antibakterielle midler
- Antibiotika, antineoplastisk
- Antifungale midler
- Bendamustine hydrochlorid
- Sirolimus
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- EudraCT-No.: 2009-014844-13
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .